 
Cardiology News Cardiovascular Systems Enrolls First Patient In CALCIUM 360 Degree Clinical Trial Fri, 20 Nov 2009 05:00:00 PST Cardiovascular Systems, Inc. (CSI) (Nasdaq:CSII), announces the first patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company's 360° Clinical Series. The CALCIUM 360° study will evaluate the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI's Diamondback 360® PAD System, a minimally invasive catheter for treating PAD anywhere in the leg. The first procedure was performed successfully by Dr. Results Presented From First Study Reviewing Convergent Approach To Treating Atrial Fibrillation At American Heart Association Scientific Sessions Fri, 20 Nov 2009 02:00:00 PST nContact Surgical, Inc. ("nContact"), a leader in the investigation of devices for minimally-invasive treatment for heart conditions, announced that data from a poster was presented at the American Heart Association Scientific Sessions in Orlando. The study demonstrated that the convergent approach, which combines surgical and electrophysiological expertise, appears to be a good strategy to achieve short term success in patients with long standing persistent atrial fibrillation (AF). VerifyNow(R) System Highlighted In POPular Study Comparing Platelet Reactivity Tests Fri, 20 Nov 2009 02:00:00 PST Accumetrics, Inc., developer of the VerifyNow System, the first point-of-care method for measuring platelet reactivity, announces that its market-leading VerifyNow P2Y12 Test was one of multiple methods evaluated in the POPular study, which was presented during a Late Breaking Clinical Trials session at the American Heart Association's annual Scientific Sessions. Telephone-Delivered Care For Treating Depression After Coronary Artery Bypass Graft Surgery Appears To Improve Outcomes Fri, 20 Nov 2009 01:00:00 PST Patients who received telephone-delivered collaborative care for treatment of depression after coronary artery bypass graft surgery reported greater improvement in measures of quality of life, physical functioning and mood than patients who received usual care, according to a study in the November 18 issue of JAMA. The study is being released early online because of its presentation at an American Heart Association scientific conference. Clinical Data, Inc. Initiates Phase III Trial Of Stedivaze For Cardiac Stress Testing Fri, 20 Nov 2009 01:00:00 PST Clinical Data, Inc. (NASDAQ: CLDA) announced that it has enrolled the first patient in its initial Phase III trial of Stedivaze™, a potential best-in-class vasodilator for use in cardiac stress testing. The study will evaluate the safety and efficacy of Stedivaze (apadenoson) for use as a pharmacologic stress agent in myocardial perfusion imaging (MPI), a method for detecting defects in the blood supply to the heart.  |
